Genetic testing for Alzheimer's and long-term care insurance

Health Affairs

Volumn 29, Issue 1, 2010, Pages 102-108

  Taylor Jr , Donald H ^a   Cook Deegan, Robert M ^a   Hiraki, Susan ^b   Roberts, J Scott ^c   Blazer, Dan G ^a,d   Green, Robert C ^e,f  

^a DUKE UNIVERSITY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d University of Michigan ^*  (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONSUMER ATTITUDE; GENETIC RISK; GENETIC SCREENING; GENETIC TRAIT; GENOTYPE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SERVICE; HEALTH SURVEY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NURSING HOME;

AGED; ALZHEIMER DISEASE; ASSISTED LIVING FACILITIES; COMMUNITY HEALTH SERVICES; FEMALE; GENETIC TESTING; HEALTH POLICY; HEALTH SERVICES FOR THE AGED; HUMANS; INSURANCE, LONG-TERM CARE; MALE; MEDICAID; NURSING HOMES; ORGANIZATIONAL OBJECTIVES; OUTCOME ASSESSMENT (HEALTH CARE); PRIVATE SECTOR; UNITED STATES;

EID: 77957366360     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2009.0525     Document Type: Article

References (24)

1. Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood). 2005;24(2):483-90.
2. Kaiser Family Foundation. Medicaid/CHIP: long-term care [Internet]. Menlo Park (CA) : KFF; [cited 2009 Nov. 19]. Available from: http://www.kff.org/ medicaid/longtermcare.cfm
3. Brown JR, Finkelstein A. The private market for long-term care insurance in the United States: a review of the evidence. J Risk Uncertaint. 2009;76:5-29.
4. Kemper P, Komisar HL, Alecxih L. Long-term care over an uncertain future: what can current retirees expect? Inquiry. 2005;42(4):335-50.
5. Finkelstein A, McGarry K, Sufi A. Dynamic inefficiencies in insurance markets: evidence from long-term care insurance. Am Econ Rev. 2005;95:224-8.
6. Langa KM, Chernew ME, Kabeto MU, Herzog AR. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16(11):770-8.
7. Taylor DH Jr., Schenkman M, Zhou J, Sloan FA. The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons. J Gerontol B Psychol Sci Soc Sci. 2001;56(5):S285-93.
8. Brown JR, Finkelstein A. The interaction of public and private insurance: Medicaid and the long-term care insurance market. Amer Econ Rev. 2008;98(3):1083-1102.
9. Merlis M. Private long-term care insurance: who should buy it and what should they buy? Menlo Park (CA) : Kaiser Family Foundation; 2003. p. iii-viii.
10. Murtaugh CM, Kemper P, Spillman BC. Risky business: long-term care insurance underwriting. Inquiry. 1995;32(3):271-84.
11. Temkin-Greener H, Mukamel DB, Meiners MR. Long-term care insurance underwriting: understanding eventual claims experience. Inquiry. 2000/01;37(4):348-58.
12. Wiener JM, Illston LH, Hanley RJ. Sharing the burden: strategies for public and private long-term care insurance. Washington (DC) : Brookings Institution; 1994.
13. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease: a meta analysis. JAMA. 1997;278(16):1349-56.
14. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc. 1992;40(3):221-4.
15. Blazer D, Burchett B, Service C, George LK. The association of age and depression among the elderly: an epidemiologic exploration. J Gerontol A Biol Sci Med Sci. 1991;46(6):M210-5.
16. Blazer D, Burchett B, Fillenbaum G. APOE e4 and low cholesterol as risks for depression in a biracial elderly community sample. Am J Geriatr Psychiatry. 2002;10(5):515-20.
17. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broekhoven C, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam study. Arch Neurol. 1998;55(7):964-8. (Pubitemid 28335115)
18. BU Alzheimer's Disease Study. REVEAL [Internet]. Boston (MA) : Boston University; [cited 2009 Nov. 19]. Available from: http://www.bu.edu/alzresearch/ research/genetics/reveal/index.html
19. Roberts JS, La Russe SA, Katzen H, Whitehouse PJ, Barber M, Post SG, et al. Reasons for seeking genetic susceptibility testing among firstdegree relatives of people with Alzheimer's disease. Alzheimer's Dis Assoc Disord. 2003;17(2):86-93.
20. Blazer DG, Fillenbaum GC, Gold DT, Burchett BM, Hays JC. APOE e4 as a predictor of subjective quality of life in a biracial older person community sample. J Aging Health. 2003;15(4):645-60.
21. National Conference of State Legislatures. Genetics and life, disability, and long-term care insurance [Internet]. Denver (CO) : NCSL; [cited 2009 Nov. 19]. Available from: http://www.ncsl.org/IssuesResearch/Health/ GeneticNondiscriminationLawsin LifeDisability/tabid/14283/Default.aspx
22. Genetics and Public Policy Center. Direct-to-consumer genetic testing companies [Internet]. Washington (DC) : Genetics and Public Policy Center; [last updated 2009 May 27; cited 2009 Nov. 19]. Available from: http://www.dnapolicy. org/resources/DTCcompanieslist.pdf. This document lists thirty-nine companies providing direct-toconsumer genetic testing as of 27 May 2009.
23. Skeehan K, Heaney C, Cook-Deegan R. Impact of gene patents and licensing practices on licensing practices on access to genetic testing for Alzheimer's disease. Durham (NC) : Duke University Center for Genome Ethics, Law, and Policy; 2009 Feb.
24. Pokorski R. A test for the insurance industry. Nature. 1998;391(6670):835-6.